New Stock Listings - The new stock "Zhongjie Automobile" (code: 301560) is listed at an issuance price of 16.50[1] Rights Issues and Offers - Cash option for "AVIC Capital" (code: 600705) is available from April 23 to April 25, 2025[1] - Tender offer for "ST Xinchao" (code: 600777) is open from April 23 to May 22, 2025[1] - "ST Puli" (code: 300630) will enter the delisting arrangement period starting April 28, 2025[1] Market Alerts - "Guoguang Chain" (code: 605188) has reported severe abnormal fluctuations[1] - "Dongfang Tong" (code: 300379) also reported severe abnormal fluctuations[1] Other Announcements - "Huili B" (code: 900939) has a recent announcement linked to its trading activities[1] - "Zhejiang Rongtai" (code: 603119) has a recent announcement linked to its trading activities[1] - "ST Jiuyou" (code: 600462) has a recent announcement linked to its trading activities[1]

Core Viewpoint - The Shenzhen Stock Exchange has decided to terminate the listing of ST Puli's stock and convertible bonds due to serious financial fraud issues, marking a significant change in the company's status in the capital market [4][5]. Financial Fraud and Consequences - ST Puli was found to have inflated its profits by a total of 669 million yuan, which accounted for 73.83% of the total reported profits for 2021 and 2022 [5][6]. - The company's core management, including the chairman and general manager, were involved in orchestrating the financial fraud, leading to severe penalties including a total fine of 24.2 million yuan and market bans for key executives [6][7]. Revenue Trends - In 2020, the company reported revenue of 1.189 billion yuan, a year-on-year increase of 25.10%, and a net profit of 407 million yuan, up 35.30% [6]. - Revenue continued to grow in 2021, reaching 1.509 billion yuan (up 26.94%), but net profit only slightly increased to 417 million yuan (up 2.25%) [6]. - In 2022, revenue rose to 1.619 billion yuan (up 7.31%), but net profit fell significantly to 295 million yuan, a decrease of 29.20% [6][7]. - By 2023, revenue dropped to 1.304 billion yuan, a decline of 19.43%, with net profit plummeting to 85.92 million yuan, down 70.87% [7]. Product Performance - The company's major products, particularly cardiovascular drugs, allergy medications, antibiotics, and digestive drugs, experienced significant revenue declines in 2023 [7]. - The overall business environment for ST Puli is deteriorating, with challenges expected to intensify in 2024, despite some products showing temporary growth [7]. Market Implications - The termination of ST Puli's listing serves as a warning to the pharmaceutical industry about the importance of compliance and maintaining core competitiveness to gain market trust [7].

Core Viewpoint - The Shenzhen Stock Exchange has announced the termination of the listing of Hainan Puli Pharmaceutical Co., Ltd. due to significant financial fraud, which involved false reporting of profits totaling 669 million yuan over two years, constituting 73.83% of the reported profits for those years [1][3][5]. Financial Fraud Details - Puli Pharmaceutical falsely recognized sales revenue and profits by fabricating sales of finished and raw pharmaceutical products, leading to inflated revenues of 436 million yuan in 2021 and 456 million yuan in 2022, which represented 28.90% and 25.23% of the reported revenues for those years, respectively [4][5]. - The company also misreported revenues from trading activities, resulting in additional inflated revenues of 78 million yuan in 2021 and 59 million yuan in 2022, accounting for 5.17% and 3.28% of the reported revenues [4][5]. Regulatory Actions - Following the issuance of the administrative penalty decision by the China Securities Regulatory Commission (CSRC), the Shenzhen Stock Exchange initiated the process for terminating the listing of Puli Pharmaceutical's stock and convertible bonds [7][8]. - The stock was suspended from trading on March 24, 2025, with a closing price of 2.49 yuan per share and a total market value of 1.398 billion yuan [8]. Company Background - Puli Pharmaceutical, established in 1992, specializes in drug research, production, and sales, and was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in 2017 [8]. Ongoing Investigations and Consequences - The CSRC has indicated that administrative penalties and forced delisting are not the end of the matter, as they will pursue comprehensive accountability for those involved in the financial fraud [12]. - The CSRC has also emphasized the importance of protecting investors' rights and will assist affected investors through various legal means [12].

星标 ★ IPO日报 精彩文章第一时间推送 4月18日晚间，海南普利制药股份有限公司（300630.SZ，以下简称"*ST普利"或"普利制药"）发布公告，公司于2025年4月18日收到深交 所《关于海南普利制药股份有限公司股票及可转换公司债券终止上市的决定》。深圳证券交易所决定终止公司股票及可转债上市。 公司股票及可转债进入退市整理期的起始日为2025年4月28日，退市整理期为十五个交易日，预计最后交易日期为2025年5月21日。 制图：佘诗婕 虚增利润近7亿 今年3月，上市公司发布公告称，收到证监会行政处罚决定书。 2021年至2022年，普利制药通过虚构成品药和原料药销售业务的方式，虚假确认药品销售收入和利润。 其中，2021年多计营业收入 436004495.01元，占当年披露营业收入的28.90%，对应营业成本128197101.98元，多计利润总额290175562.61元，占当年披露利润 总额的 62.06% ；2022年多计营业收入455776233.78元，占当年披露营业收入的25.23%，对应营业成本69013203.17元，多计利润总 额 379066467.07元，占当年披露利润总额的8 ...

| 证券代码：300630 | 证券简称：*ST 普利 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券可能被终止上市的风险提 示公告 3、根据《创业板股票上市规则》第 10.1.9 条及《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》规定，若上市公司股票被终止上市 的，可转换公司债券（以下简称"可转债"）同步终止上市或者挂牌。 一、公司股票可能触及的终止上市情形 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、海南普利制药股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日 收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《行政处罚决 定书》（以下简称"《决定书》"），认定公司 2021 年、2022 年年度报告存在 虚假记载，同时，2021、2022 年虚假记载的营业收入金额合计达 1,029,037,811.01 元，且占该 2 年披露的年度营业收入合计 ...

Group 1 - *ST Jiyuan (300108.SZ) is expected to have a negative net asset by the end of 2024, facing potential delisting risk due to uncertain audit report opinion [1] - *ST Puli (300630.SZ) may face mandatory delisting as its 2021 and 2022 annual reports contain false records [1] - *ST Navigation (688282.SH) reported negative net profit for 2023 and revenue below 100 million, with 2024 performance forecast still negative, facing delisting risk [1] Group 2 - *ST Yinjian (300020.SZ) received an audit report with no opinion for 2023, and is undergoing 2024 audit, facing potential delisting risk [1] - *ST Dongfang (600811.SH) has seen its stock price close below 1 yuan for 15 consecutive trading days and is under investigation for information disclosure violations, facing delisting risks [1] - *ST Tongmai (603559.SH) received an audit report with no opinion for 2023 and is expected to report losses in 2024, facing potential delisting risk [1] Group 3 - *ST Furun (600070.SH) has seen its stock price close below 1 yuan for 17 consecutive trading days and has a market value below 500 million, with negative profit forecast for 2024, facing delisting risks [2] - *ST Xintong (600289.SH) received an audit report with no opinion for 2023, and may face financial delisting risks after the 2024 report [2] - *ST Weidi (603023.SH) is under delisting risk warning due to unmet financial indicators for 2023, and may face delisting if 2024 annual report remains unsatisfactory [2]

2、根据《创业板股票上市规则》第 10.5.8 条相关规定，公司股票及可转债 自 2025 年 3 月 24 日起停牌。 | 证券代码：300630 | 证券简称：*ST 普利 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | 海南普利制药股份有限公司 关于公司股票及可转换公司债券可能被终止上市的风险提 示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、海南普利制药股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日 收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《行政处罚决 定书》（以下简称"《决定书》"），认定公司 2021 年、2022 年年度报告存在 虚假记载，同时，2021、2022 年虚假记载的营业收入金额合计达 1,029,037,811.01 元，且占该 2 年披露的年度营业收入合计金额的 31.04%；虚假记载的利润总额 金额合计达 669,242,029.68 元，且占该 2 年披露的年度利润总额合计金额的 ...

| 证券代码：300630 | 证券简称：*ST 普利 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | 海南普利制药股份有限公司 关于 2025 年第一季度可转换公司债券转股情况及股票、可转 债交易相关风险提示的公告 1、"普利转债"转股时间：2021年8月23日至2027年2月8日；转股价格：人 民币11.22元/股；债券代码：123099。 2、2025年第一季度共有3,288,594张"普利转债"完成转股（票面金额共计 328,859,400元人民币），共计转成109,533,626股"普利制药"股票。 3、截至2025年3月31日，公司剩余可转债为2,022,669张，剩余票面总金额为 202,266,900元人民币。 4、海南普利制药股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日收 到中国证券监督管理委员会（以下简称"中国证监会"）下发的《行政处罚决定 书》（以下简称"《决定书》"），认定公司 2021 年、2022 年年度报告存在虚假记 载，同时，2021、2022 年虚假记载的营业收入金额 ...

关于向深圳证券交易所提交听证申请暨公司股票及可转换 | 普利 | 证券代码：300630 | 证券简称：*ST | 公告编号：2025-040 | | --- | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | | 海南普利制药股份有限公司 公司债券可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、海南普利制药股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日 收到中国证券监督管理委员会（以下简称"中国证监会"）下发的《行政处罚决 定书》（以下简称"《决定书》"），认定公司 2021 年、2022 年年度报告存在 虚假记载，同时，2021、2022 年虚假记载的营业收入金额合计达 1,029,037,811.01 元，且占该 2 年披露的年度营业收入合计金额的 31.04%；虚假记载的利润总额 金额合计达 669,242,029.68 元，且占该 2 年披露的年度利润总额合计金额的 73.83%。前述事实触及《深圳证券交易所创业板股票上市规则（2024 ...

普利制药重大财务造假案处罚落地：虚增利润超总营收 50％被强制退市，实控人范敏华罚款500万元、市场禁入 10年 河南泽槿律师事务所主任付建接受本报记者采访表示，"普利制药的行为已构成信息披露违法，且远超《深圳证券 交易所创业板股票上市规则(2024年修订)》规定的重大违法强制退市情形标准。本案中对主管人员的处罚加大了 对财务造假案件的处罚力度，提高违法成本，能够有效防止类似事件发生。因公司财务造假而遭受损失的投资 者，可通过中证投服中心运用支持诉讼等方式维权，普利制药需对投资者的损失承担相应赔偿责任。" 财务造假 普利制药成立于1992年，销售产品主要为处方药，涵盖抗过敏类药物、解热镇痛类药物、抗生素类药物、消化类 药物等领域。2017年3月28日，普利制药成功在深交所创业板上市，每股发行价11.49元，首日报收16.55元/股。而 后自2017年3月29日起连拉10个一字涨停，2018年5月8日，股价达到最高点112元/股。2017年—2020年，普利制药 业绩保持稳定增长，其收入分别为3.25亿元、6.24亿元、9.5亿元、11.89亿元，归母净利润分别为0.98亿元、1.81亿 元、3.01亿元、4. ...